Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Omega-3 wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
2 of 2 studies with measurable effects showed benefit.
Top outcomes
Verdict
Probably helps
18 of 27 studies with measurable effects showed benefit.
Top outcomes
750-1500mg daily in divided doses
With fat-containing food (improves absorption), Divided into 2-3 doses due to short half-life, With a choline source
Aniracetam powder or capsules
2-3g combined EPA+DHA daily
With meals containing fat
Triglyceride form fish oil
1-2 weeks
30-60 minutes
1-2 hours
Per dose
4-8 weeks
2-4 weeks
Immediate
4-12 weeks
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Clinical efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors, in patients with cognitive impairment: a comparative open study
CNS neuroscience & therapeutics (2012) · Observational · n=276
In patients treated with aniracetam, all studied parameters were adequately maintained at 6 and 12 months, while emotional state was significantly improved at 3 months.
[Clinical study on a randomized, double-blind control of Shenwu gelatin capsule in treatment of mild cognitive impairment]
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica (2007) · Rct · n=166
Shenwu gelatin capsule has certain effects on mild cognitive impairment.
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
The New England journal of medicine (2019) · Rct · n=25871
During a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the n-3 group and in 419 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24).
Omega-3 fatty acids for intermittent claudication
The Cochrane database of systematic reviews (2024) · Meta analysis · n=1830
Omega-3 compared with a control may have little to no effect on ankle-brachial index (MD -0.02, 95% CI -0.08 to 0.04; 3 studies, 168 participants; very low-certainty evidence).
A systematic review and meta-analysis of the omega-3 fatty acids effects on brain-derived neurotrophic factor (BDNF)
Nutritional neuroscience (2024) · Meta analysis · n=587
The present systematic review and meta-analysis indicate the efficacy of omega-3 FAs in increasing the serum concentration of BDNF.
Based on limited RCTs (n=166, n=64) and observational studies (n=276) in cognitive impairment populations. Meta-analysis effect size 0.439 suggests moderate benefit. Studies primarily in elderly/dementia patients, not healthy adults. Fat-soluble compound requiring food intake for absorption.
Based on multiple meta-analyses showing EPA-dominant formulas >1g/day most effective. Effects plateau around 2-2.5g. Adjunctive use with antidepressants shows better outcomes than monotherapy.
AI-estimated from published studies. Interpret as directional guidance.
Omega-3 has a higher evidence score (9/10 vs 4/10) and wins in 2 of 3 categories.
For support mood, Omega-3 has a higher relevance score (88 vs 50).
No known interactions between Aniracetam and Omega-3 have been documented in our database. However, always consult a healthcare provider before combining supplements.